Asset profile
Diroximel fumarate · Vumerity
Small molecule
Evidence outlook
Approved: Multiple Sclerosis (label: adults; clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive...)
Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.
track record: Partial signal
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. Pick an indication; Research unlocks the trials, endpoints, key results and grades.
Competitive landscape
44 competitors in this universe: 3 direct rivals (same mechanism and indication), 0 same-class, 41 same-indication.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials |
|---|---|---|---|---|---|
| Diroximel Fumarate (Vumerity): this drug | Approved | Small molecule | Nrf2 pathway (fumaric acid ester) | ||
| Bafiertam | Approved | Small molecule | Nrf2 pathway (fumaric acid ester) | ||
| Dimethyl Fumarate (Tecfidera) | Approved | Small molecule | Nrf2 pathway (fumaric acid ester) | ||
| DRF | Approved | Small molecule | Nrf2 pathway (fumaric acid ester) | ||
| Aldesleukin (Proleukin) | Approved | Recombinant Cytokine (il-2) | Interleukin-2 receptor (IL-2R) | ||
| Alemtuzumab | Approved | Monoclonal antibody | CD52 | ||
| Cladribine (MAVENCLAD®) | Approved | Small molecule | Adenosine deaminase-resistant purine analog, DNA synthesis machinery in lymphocytes | ||
| Copaxone | Approved | Peptide | Myelin basic protein-mimetic immunomodulation | ||
| Fampridine (Ampyra / Fampyra) | Approved | Small molecule | Potassium Channel Blocker, Voltage-gated potassium channel (Kv), Voltage-gated potassium channels (Kv1/Shaker/KCNA family) | ||
| Fingolimod (Gilenya) | Approved | Small molecule | Sphingosine 1-phosphate receptor (S1PR, specifically S1P1), S1P receptor, Sphingosine-1-phosphate receptors (S1P1, S1P3, S1P4, S1P5) | ||
| Interferon Beta-1a (Avonex) | Approved | Biologic (subtype unspecified) | Type I Interferon receptor (IFNAR) | ||
| Interferon Beta-1b | Approved | Biologic (subtype unspecified) | Interferon beta receptor (type I IFN signaling), Type I interferon receptor | ||
| Interferon-Beta1 | Approved | Biologic (subtype unspecified) | Type I interferon receptor | ||
| Mayzent | Approved | Small molecule | S1P receptor | ||
| Natalizumab (Tysabri) | Approved | Monoclonal antibody | α4 integrin | ||
| Ocrelizumab | Approved | Monoclonal antibody | CD20 |
…and 29 more. Research shows the complete landscape.
Unlock the full comparison
Research adds each competitor's evidence grade and sourced trial results, aligned per race, so you can see who actually has the data.
Upcoming events
(3 total)
Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.
2026 (1)
December 2026 (1)
What to watch
2027 (1)
January 2027 (1)
What to watch
2034 (1)
July 2034 (1)
What to watch
All registered studies
Every ClinicalTrials.gov study of this drug's own program, grouped by indication and phase. Research unlocks the studies themselves: titles, statuses, dates and featured-trial cross-links.